Skip to main content

Recombinant Human IL-13 Protein

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-35018

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-35018-100ug
NBP2-35018-10ug
NBP2-35018-1mg
NBP2-35018-500ug

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity, SDS-PAGE

Product Specifications

Description

A single non-glycosylated polypeptide chain containing 112 amino acids corresponding to IL-13 Source: E. coli

Uniprot ID: P35225

Amino Acid Sequence: GPVPPSTALR ELIEELVNIT QNQKAPLCNG SMVWSINLTA GMYCAALESL INVSGCSAIE KTQRMLSGFC PHKVSAGQFS SLHVRDTKIE VAQFVKDLLL HLKKLFREGR FN

Purity

> 97 % pure by SDS-PAGE and HPLC

Endotoxin Level

Less than 1 EU/ug of IL-13 as determined by LAL method.

Predicted Molecular Mass

12.5 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Activity

IL-13 protein is fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 1 ng/ml, corresponding to a specific activity of > 1.0 x 10^6 IU/mg

Protein / Peptide Type

Recombinant Protein

Scientific Data Images for Recombinant Human IL-13 Protein

SDS-PAGE: Recombinant Human IL-13 Protein [NBP2-35018]

SDS-PAGE: Recombinant Human IL-13 Protein [NBP2-35018]

SDS-Page: Human IL-13 Protein [NBP2-35018]

Formulation, Preparation and Storage

NBP2-35018
Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
Preservative 5% Trehalose
Concentration Lyoph
Reconstitution Recommended to centrifuge prior to opening. Reconstitute in 20 mM HCl to a concentration of 0.1-1.0mg/mL. Apportion stock solutions into working aliquots and store at
Format Carrier-Free
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store at -20 to -70C as supplied. After reconstitution, store at 2 to 8C for 1 month and at -20 to -70C for long term storage. Avoid repeated freeze-thaw cycles.

Background: IL-13

Human Interleukin-13 (IL-13) is expressed by the IL13 gene located on the chromosome 5 and secreted by many cell types, especially T helper type 2 (Th2) cells. The high solution from of IL-13 reported to be a monomer with two internal disulfide bonds that contribute to a bundled four alpha-helix configuration. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 exerts anti- inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1beta, TNF-alpha, IL-6 and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching resulting in increased production of IgE. Human, mouse and rat IL-3 share low homology, but have cross species activity.

Long Name

Interleukin 13

Alternate Names

IL13, NC30, P600

Gene Symbol

IL13

UniProt

Additional IL-13 Products

Product Documents for Recombinant Human IL-13 Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Recombinant Human IL-13 Protein

This lyophilized preparation is stable at 2-8 degrees C, but should be kept at -20 degrees C for long term storage, preferably desiccated. Upon reconstitution, the preparation is most stable at -20 to -80 degrees C, and can be stored for one week at 2-8 degrees C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 degrees C to -80 degrees C. Avoid repeated freeze/thaw cycles.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...